Meabco’s product portfolio is based on the combination of BP-Cx-1 and metal ions of known therapeutic potential.  

BP-Cx-1

BP-Cx-1, a globular polydentant ligand, is based on acid polymers of the benzo-poly-carbonic family. for further information on

BP-Cx1 press here

 
BP-C1

BP-C1 is based on a combination of BP-Cx-1 and platinum.  It contains approximately 100 times less platinum than ordinary

doses of Cisplatin used in chemotherapeutical drugs, resulting in a much enhanced safety profile.  At the same time, clinical

efficacy is maintained due to the carrier effect of the polymer. for further information on BP-C1 press here

 
BP-C2

The company’s second product is BP-C2, which is based on BP-Cx-1 combined with molybdenum salts.  BP-C2 is in preclinical

development for prevention of side effects arising from cancer radiotherapy, nuclear radiation and irradiation at large.

In addition, BP-C2 is being developed for bio-defense purposes. for further information on BP-C2 press here